The $101M Startup That Wants to Kill Tepezza's Monopoly at the Root

Built for the Couch, Not the Clinic

Tepezza's practical limitations are well documented. Patients need eight IV infusions over roughly five months, each requiring a trip to an infusion center. The drug has been linked to hearing problems in some patients, along with hyperglycemia, nausea, and hair loss. And at approximately $18,700 per vial, insurance fights are common.

Ethyreal is designing ETHY-001 to sidestep several of those pain points. The drug uses subcutaneous injection (a quick shot under the skin, like insulin) instead of an IV drip. It also incorporates half-life extension technology to allow less frequent dosing. The company says it's even planning an autoinjector device, which would let patients self-administer at home.

For patients managing a chronic condition, the difference between sitting in an infusion chair every three weeks and giving yourself a shot at home is enormous. Convenience isn't a luxury in chronic disease; it's a competitive weapon.

The Team and the Money

Ethyreal's $101 million war chest was assembled in two tranches. Atlas Venture and Medicxi Ventures co-led the Series A, with participation from Nandi Life Sciences and Checkpoint Capital. Avoro Capital led the Series B, and all the Series A investors came back for seconds.

The company is led by CEO Niranjan Kameswaran, Ph.D., a former Atlas Venture entrepreneur-in-residence who previously served as COO of Resonance Medicine and SVP of Strategy at Kala Pharmaceuticals. The board is chaired by Simon Read, Ph.D., a partner at Atlas who founded Mariana Oncology and was chief scientific officer at Ra Pharma.

Ethyreal plans to present preclinical data on ETHY-001 at the Endocrine Society's annual meeting, with a first-in-human trial targeted for the second half of 2026.

A Crowded Race Is Getting More Crowded

Ethyreal isn't the only company that smells blood in the water. The TED competitive landscape has exploded over the past two years.

Viridian Therapeutics is the most advanced challenger, with two anti-IGF-1R antibodies in Phase 3 trials. Its lead drug, veligrotug, received Breakthrough Therapy Designation from the FDA in May 2025, with a potential U.S. launch in the second half of 2026. Viridian is also developing a subcutaneous version called VRDN-003.

Beyond the IGF-1R space, Immunovant and Harbour BioMed developed batoclimab, an FcRn antagonist (a drug that reduces the pathogenic antibodies themselves), but its Phase 3 trials for TED failed their primary endpoints, and the companies are reviewing future plans. Tourmaline Bio is testing an anti-IL-6 antibody for TED. Sling Therapeutics is developing what could become the first oral pill for the disease. Even Kriya Therapeutics is working on a gene therapy approach.

The common thread: everyone agrees that a $2 billion market with a single approved drug, low patient penetration (Amgen says it's still in the single digits), and real clinical limitations is ripe for disruption.

The Big Question

Ethyreal's TSHR-blocking approach is scientifically elegant. If you can shut down the autoimmune attack at its origin, you could theoretically prevent both the thyroid dysfunction and the eye damage. That's the pitch.

But "theoretically" is doing a lot of heavy lifting. ETHY-001 hasn't been tested in a single human yet. The company still needs to prove that blocking TSHR is sufficient to control a disease driven by multiple pathways, including the IGF-1R signaling and downstream inflammation that Tepezza already addresses. Biology is messy, and upstream targets don't always deliver the clean results that diagrams on a slide deck suggest.

Still, $101 million in venture backing, a differentiated mechanism, a patient-friendly delivery system, and a market where Tepezza's dominance looks increasingly vulnerable: that's a recipe worth watching. Ethyreal will need years of clinical data to prove the thesis. But if ETHY-001 works, it won't just challenge Tepezza. It could redefine how doctors think about treating thyroid autoimmune disease altogether.

Sanofi's Plan B Just Lost Its Plan B

Sanofi just halted another late-stage trial, and it's not the first pipeline disappointment this year. With Dupixent's patents expiring around 2031 and its top successor underwhelming Wall Street, the pressure to find a Plan D is getting very real.